Stay updated on Nivolumab After SIRT for HCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab After SIRT for HCC Clinical Trial page.

Latest updates to the Nivolumab After SIRT for HCC Clinical Trial page
- Check7 days agoChange DetectedSite revision updated to v3.4.3, replacing v3.4.2.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.4.2 was added and the previous funding-status notice v3.4.1 was removed. The study details and page content remain unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedA site-wide government funding notice was added at the top of the page, clarifying possible delays and directing users to cc.nih.gov and opm.gov, and the page revision was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check50 days agoChange DetectedShow glossary has been added, along with labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' and a site revision note 'Revision: v3.4.0'. The previous labels 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data' and revision note 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check64 days agoChange DetectedRevision: v3.3.4 was added and the previous Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check85 days agoChange DetectedFooter shows Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2; this does not affect the trial content, eligibility criteria, or study outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab After SIRT for HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab After SIRT for HCC Clinical Trial page.